CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-9.14%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.68B
AUM Growth
+$1.68B
(-32%)
Cap. Flow
-$192M
Cap. Flow
% of AUM
-11.44%
Top 10 Holdings %
Top 10 Hldgs %
50.05%
Holding
96
New
8
Increased
9
Reduced
34
Closed
18
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
$31.9M |
| 2 |
Ventyx Biosciences
VTYX
|
$15.1M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$14.7M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$14.6M |
| 5 |
Adicet Bio
ACET
|
$13.1M |
Top Sells
| 1 |
Atea Pharmaceuticals
AVIR
|
$29M |
| 2 |
AGEN
Agenus
AGEN
|
$25.2M |
| 3 |
Revolution Medicines
RVMD
|
$17.9M |
| 4 |
Ascendis Pharma
ASND
|
$16.1M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$15.4M |
Sector Composition
| 1 | Healthcare | 99.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Erasca
ERAS
$445M
| $164M | 9.74% | 10,505,550 | – | – |
|
|
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $144M | 8.58% | 3,025,000 +182,703 | +6% | +$8.71M |
|
3
Design Therapeutics
DSGN
$315M
| $116M | 6.93% | 5,440,453 +75,603 | +1% | +$1.62M |
|
|
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $73.1M | 4.35% | 1,848,024 | – | – |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $66M | 3.92% | 4,639,995 -80,500 | -2% | -$1.14M |
|
6
Monte Rosa Therapeutics
GLUE
$296M
| $61.3M | 3.65% | 3,002,199 -100,000 | -3% | -$2.04M |
|
|
7
Revolution Medicines
RVMD
$7.1B
| $61.2M | 3.64% | 2,431,852 -712,848 | -23% | -$17.9M |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $54.5M | 3.24% | 3,565,901 +194,987 | +6% | +$2.98M |
|
9
Tango Therapeutics
TNGX
$747M
| $53.1M | 3.16% | 4,899,185 +1,000,000 | +26% | +$10.8M |
|
10
Avidity Biosciences
RNA
$5.99B
| $47.8M | 2.84% | 2,012,115 -150,000 | -7% | -$3.57M |
|
|
VERV
11
DELISTED
Verve Therapeutics
VERV
| $40.9M | 2.43% | 1,109,224 +400,000 | +56% | +$14.7M |
|
|
12
Beam Therapeutics
BEAM
$1.66B
| $39.8M | 2.37% | 500,000 +400,000 | +400% | +$31.9M |
|
13
Immuneering
IMRX
$245M
| $37.2M | 2.21% | 2,302,626 +50,000 | +2% | +$808K |
|
14
BioAtla
BCAB
$26.7M
| $33M | 1.96% | 1,681,115 -134,431 | -7% | -$2.64M |
|
15
Cytokinetics
CYTK
$4.23B
| $31.9M | 1.9% | 700,000 -300,000 | -30% | -$13.7M |
|
16
Tarsus Pharmaceuticals
TARS
$2.47B
| $31.6M | 1.88% | 1,403,331 -41,500 | -3% | -$934K |
|
|
RAIN
17
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $30M | 1.78% | 2,326,660 | – | – |
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $29.6M | 1.76% | 625,000 -300,000 | -32% | -$14.2M |
|
19
Stoke Therapeutics
STOK
$1.08B
| $28.4M | 1.69% | 1,182,362 -95,914 | -8% | -$2.3M |
|
|
CNTA
20
Centessa Pharmaceuticals
CNTA
$2.25B
| $28M | 1.67% | 2,489,894 +762,621 | +44% | +$8.59M |
|
21
BridgeBio Pharma
BBIO
$9.89B
| $27.8M | 1.66% | 1,668,909 -100,000 | -6% | -$1.67M |
|
22
Biomea Fusion
BMEA
$116M
| $23.6M | 1.41% | 3,170,872 | – | – |
|
|
AMAM
23
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $22.5M | 1.34% | 2,486,386 | – | – |
|
|
JBIO
24
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $21.6M | 1.28% | 1,830,691 -200,000 | -10% | -$2.36M |
|
25
Olema Pharmaceuticals
OLMA
$375M
| $20.3M | 1.21% | 2,169,871 -903,614 | -29% | -$8.46M |
|